Dimitra Veltsista is a consultant neurologist-neurphysiologist at the University Hospital of Patras since 2016. Her main responsibilities include, being in charge of the Department of Clinical Neurophysiology, a member of the NMD multidisciplinary team and Botulinum toxin treatments.
Her research interests focus on all aspects of clinical neurophysiology, particularly those related to neuromuscular diseases such as motor neuron disease, auto-immune neuropathies & myopathies. They include:
- Diagnostic applications of ultrasound in myopathies and peripheral nerve disorders.
- Development of electromyographic programs and custom-build software programs for signal analysis, in collaboration with Department of Computer Engineering.
- Applications of magnetic stimulation in the study of central and peripheral nervous system diseases.
- Clinical studies aiming to assess the response of patients with varied PNS disorders to treatment trials with new medications.
She is a member of the Myasthenia Branch of Hellenic Neurological Society and junior representative of Hellenic Neurological Society in peripheral neuropathies and clinical neurophysiology. She has served on scientific Panels of European Academy of Neurology for 2021-2023.
She is the author of 18 peer reviewed articles in international journals and has been an invited speaker in 12 national meetings. She has been involved in 4 international multi-center studies (phase II & III) on neuromuscular diseases as sub-investigator.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.